Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000038541 | SCV000062219 | likely benign | not specified | 2018-02-23 | criteria provided, single submitter | clinical testing | p.Arg989Lys in exon 19 of SOS1: This variant is not expected to have clinical si gnificance because the arginine (Arg) residue at position 989 is not conserved t hrough species, with 7 mammals (lesser egyptiam jerboa, naked mole rat, alpaca, bactrian camel, hedgehog, cape elephant shrew and manatee) having a lysine (Lys) at this position. It has been identified in 7/62190 European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs202 043599). |
Gene |
RCV000586941 | SCV000518866 | likely benign | not provided | 2020-07-30 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000038541 | SCV000698629 | likely benign | not specified | 2024-09-16 | criteria provided, single submitter | clinical testing | Variant summary: SOS1 c.2966G>A (p.Arg989Lys) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00023 in 1491372 control chromosomes, predominantly at a frequency of 0.00031 within the Non-Finnish European subpopulation in the gnomAD database. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately 10-fold of the estimated maximal expected allele frequency for a pathogenic variant in SOS1 causing Noonan Syndrome And Related Conditions phenotype (3e-05). c.2966G>A has been reported in the literature in an individual affected with ependymoma without strong evidence for causality (Zhang_2015). This report does not provide unequivocal conclusions about association of the variant with Noonan Syndrome and Related Conditions. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 26580448). ClinVar contains an entry for this variant (Variation ID: 45357). Based on the evidence outlined above, the variant was classified as likely benign. |
Labcorp Genetics |
RCV000654932 | SCV000776838 | uncertain significance | RASopathy | 2024-01-16 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with lysine, which is basic and polar, at codon 989 of the SOS1 protein (p.Arg989Lys). This variant is present in population databases (rs202043599, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with SOS1-related conditions. ClinVar contains an entry for this variant (Variation ID: 45357). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The lysine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Eurofins Ntd Llc |
RCV000586941 | SCV000860417 | uncertain significance | not provided | 2018-04-03 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001138300 | SCV001298342 | uncertain significance | Noonan syndrome 4 | 2018-01-12 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
Illumina Laboratory Services, |
RCV001143052 | SCV001303549 | likely benign | Fibromatosis, gingival, 1 | 2018-01-12 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. |
Ambry Genetics | RCV002433506 | SCV002750106 | uncertain significance | Cardiovascular phenotype | 2024-09-25 | criteria provided, single submitter | clinical testing | The p.R989K variant (also known as c.2966G>A), located in coding exon 19 of the SOS1 gene, results from a G to A substitution at nucleotide position 2966. The arginine at codon 989 is replaced by lysine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |